Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (above 30 g/L) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g/L or below (control)).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Male and female subjects equal or above 18 yrs old.
• Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).
• Capability of understanding the purpose and risks of the study.
• Written informed consent
Locations
Other Locations
France
08_CHRU de Tours Hôpital Trousseau
RECRUITING
Chambray-lès-tours
03_APHP Hôpital Beaujon
RECRUITING
Clichy
04_CHU de Lille Hôpital Huriez
NOT_YET_RECRUITING
Lille
05_HCL Hôpital de la Croix Rousse
RECRUITING
Lyon
06_CHU de Montpellier Hôpital St Eloi
RECRUITING
Montpellier
02_CHU de Bordeaux - Hôpital Haut Leveque
RECRUITING
Pessac
01_CHU de Rennes Hôpital Pontchaillou
RECRUITING
Rennes
09_APHP Hôpital Paul Brousse
NOT_YET_RECRUITING
Villejuif
Contact Information
Primary
Loïc JACOB
loic.jacob@chu-rennes.fr
+33299282555
Time Frame
Start Date: 2025-03-26
Estimated Completion Date: 2028-04-26
Participants
Target number of participants: 400
Treatments
Experimental: 30 g/L or below
Receive Human Albumin 20% Solution when albumin serum concentration is at 30 g/L or below
Active_comparator: 20 g/L or below
receive Human Albumin 20% Solution when albumin serum concentration is at 20 g/L or below
Related Therapeutic Areas
Sponsors
Leads: Rennes University Hospital
Collaborators: Ministry of Health, France